Literature DB >> 20108094

Presentation and survival of operable esophageal cancer in patients 55 years of age and below.

A Hamouda1, M Forshaw, A Rohatgi, R Mirnezami, A Botha, R Mason.   

Abstract

BACKGROUND: The increased incidence of esophageal cancer, especially in the younger age group, should encourage early diagnosis. The perceived rarity and poor prognostic outcome of esophageal cancer in this group is based on retrospective studies. The goal of this study was to review the presentation and survival of young patients with esophageal cancer.
METHODS: This study was conducted from 2000 to 2007 in a specialized esophagogastric center. All patients who had esophageal cancer operations were included. Variables collected included ages, duration of symptoms, presenting symptoms, tumor characteristics, and follow-up data.
RESULTS: In total, 365 esophagectomies were performed for cancer, of which 76 patients were younger than aged 55 years (20.8%) and 289 were older than aged 55 years. In patients younger than aged 55 years, 15 patients had symptoms for 6 months or more, 54 had dysphagia, 35 had weight loss compared with 220 and 175 respectively of patients older than aged 55 years. On histopathology, 48 had T3 tumors (63.2%), 17 had T2 (22.4%), and 10 had T1 (13.2%) for patients younger than aged 55 years compared with 141 had T3 (48.7%), 85 had T2 (29.4%), and 55 had T1 (19%) for patients older than aged 55 years. These differences in tumor stage at presentation between groups were significant (p < 0.05 with 3DF). In-hospital mortality was 0 for the group younger than aged 55 years and 5 for those older than aged 55 years. Average follow-up was 35 (minimum, 15) months. Thirty patients had locoregional recurrence in the first group and 110 in the latter group. Survival at 1 year after surgery was 79.6%, at 2 years 65.1%, and at 5 years 42.3% compared with 78.4, 60.6, and 45.9%, respectively, for the group older than aged 55 years, but this was not significant using log-rank (p = 0.99).
CONCLUSIONS: A significant proportion (20.8%) of patients presenting with operable esophageal cancer was younger than aged 55 years. Almost two-thirds of those presenting younger than aged 55 years had T3 stage tumors, which was significantly different than those older than aged 55 years. Despite more advanced tumor stage at presentation, the prognosis of esophageal cancer for patients younger than aged 55 years is similar to those older than aged 55 years (log-rank = 0.99).

Entities:  

Mesh:

Year:  2010        PMID: 20108094     DOI: 10.1007/s00268-010-0407-6

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  19 in total

1.  Does concern about missing malignancy justify endoscopy in uncomplicated dyspepsia in patients aged less than 55?

Authors:  D Gillen; K E McColl
Journal:  Am J Gastroenterol       Date:  1999-01       Impact factor: 10.864

Review 2.  Columnar-lined esophagus in children.

Authors:  E Hassall
Journal:  Gastroenterol Clin North Am       Date:  1997-09       Impact factor: 3.806

3.  Guidelines for the management of dyspepsia.

Authors:  Nicholas J Talley; Nimish Vakil
Journal:  Am J Gastroenterol       Date:  2005-10       Impact factor: 10.864

4.  Age and alarm symptoms do not predict endoscopic findings among patients with dyspepsia: a multicentre database study.

Authors:  M B Wallace; V L Durkalski; J Vaughan; Y Y Palesch; E D Libby; P S Jowell; N J Nickl; S M Schutz; J W Leung; P B Cotton
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

5.  Esophageal adenocarcinoma in patients < or = 50 years old: delayed diagnosis and advanced disease at presentation.

Authors:  G Portale; J H Peters; C C Hsieh; A P Tamhankar; G Almogy; J A Hagen; S R Demeester; C G Bremner; T R Demeester
Journal:  Am Surg       Date:  2004-11       Impact factor: 0.688

Review 6.  Evidence-based recommendations for short- and long-term management of uninvestigated dyspepsia in primary care: an update of the Canadian Dyspepsia Working Group (CanDys) clinical management tool.

Authors:  Sander J O Veldhuyzen van Zanten; Marc Bradette; Naoki Chiba; David Armstrong; Alan Barkun; Nigel Flook; Alan Thomson; Ford Bursey
Journal:  Can J Gastroenterol       Date:  2005-05       Impact factor: 3.522

7.  Endoscopic findings and diagnoses in unselected dyspeptic patients at a primary health care center.

Authors:  I Kagevi; S Löfstedt; L G Persson
Journal:  Scand J Gastroenterol       Date:  1989-03       Impact factor: 2.423

Review 8.  Epidemiology of esophageal cancer: Orient to Occident. Effects of chronology, geography and ethnicity.

Authors:  Michio Hongo; Yutaka Nagasaki; Tomotaka Shoji
Journal:  J Gastroenterol Hepatol       Date:  2009-05       Impact factor: 4.029

Review 9.  Management guidelines for uninvestigated and functional dyspepsia in the Asia-Pacific region: First Asian Pacific Working Party on Functional Dyspepsia.

Authors:  N J Talley; S K Lam; K L Goh; K M Fock
Journal:  J Gastroenterol Hepatol       Date:  1998-04       Impact factor: 4.029

10.  Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites.

Authors:  J Powell; C C McConkey
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

View more
  7 in total

1.  Influence of young age on outcome after esophagectomy for cancer.

Authors:  Anna M J van Nistelrooij; Elrozy R Andrinopoulou; Jan J B van Lanschot; Hugo W Tilanus; Bas P L Wijnhoven
Journal:  World J Surg       Date:  2012-11       Impact factor: 3.352

2.  Higher clinical suspicion is needed for prompt diagnosis of esophageal adenocarcinoma in young patients.

Authors:  Tamar B Nobel; Michael Curry; Renee Gennarelli; David R Jones; Daniela Molena
Journal:  J Thorac Cardiovasc Surg       Date:  2019-04-16       Impact factor: 5.209

3.  Is the age of diagnosis of esophageal adenocarcinoma getting younger? Analysis at a tertiary care center.

Authors:  Alexandra Strauss; Eun Jeong Min; Qi Long; Peter Gabriel; Yu-Xiao Yang; Gary W Falk
Journal:  Dis Esophagus       Date:  2020-09-04       Impact factor: 3.429

Review 4.  Role of TFF3 as an adjunct in the diagnosis of Barrett's esophagus using a minimally invasive esophageal sampling device-The CytospongeTM.

Authors:  Anna L Paterson; Marcel Gehrung; Rebecca C Fitzgerald; Maria O'Donovan
Journal:  Diagn Cytopathol       Date:  2019-12-09       Impact factor: 1.582

5.  Association between polymorphisms in cancer-related genes and early onset of esophageal adenocarcinoma.

Authors:  I-Chen Wu; Yang Zhao; Rihong Zhai; Geoffrey Liu; Monica Ter-Minassian; Kofi Asomaning; Li Su; Chen-Yu Liu; Feng Chen; Matthew H Kulke; Rebecca S Heist; David C Christiani
Journal:  Neoplasia       Date:  2011-04       Impact factor: 5.715

6.  Adenocarcinoma of the esophagus in the young.

Authors:  Arzu Oezcelik; Shahin Ayazi; Steven R DeMeester; Joerg Zehetner; Emmanuele Abate; Joie Dunn; Kimberly S Grant; John C Lipham; Jeffrey A Hagen; Tom R DeMeester
Journal:  J Gastrointest Surg       Date:  2013-04-06       Impact factor: 3.452

7.  Outcomes of esophagectomy after noncurative endoscopic resection of early esophageal cancer.

Authors:  Solène Dermine; Mahaut Leconte; Sarah Leblanc; Bertrand Dousset; Benoit Terris; Arthur Berger; Anne Berger; Gabriel Rahmi; Vincent Lepilliez; Olivier Plomteux; Philippe Leclercq; Romain Coriat; Stanislas Chaussade; Frédéric Prat; Maximilien Barret
Journal:  Therap Adv Gastroenterol       Date:  2019-12-08       Impact factor: 4.409

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.